InMed Pharmaceuticals Files 2024 Proxy Statement

TL;DR

InMed Pharma proxy filed. Vote on Dec 18th. Key decisions ahead.

AI Summary

InMed Pharmaceuticals Inc. filed its definitive proxy statement on October 28, 2024, for its annual meeting on December 18, 2024. The company, headquartered in Vancouver, is in the pharmaceutical preparations industry. This filing outlines the agenda and proposals to be voted on by shareholders, including the election of directors and other corporate matters.

Why It Matters

This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction at the upcoming annual meeting.

Risk Assessment

Risk Level: medium — Proxy statements can indicate upcoming strategic shifts or governance changes that may impact a company's future performance and stock price.

Key Numbers

• 20241218 — Annual Meeting Date (Shareholders will vote on proposals on this date.)
• 20241028 — Filing Date (The proxy statement was officially filed with the SEC on this date.)

Key Players & Entities

• InMed Pharmaceuticals Inc. (company) — Registrant
• 20241218 (date) — Annual Meeting Date
• 20241028 (date) — Filing Date
• Vancouver (location) — Company Headquarters

FAQ

Key Financial Figures

• $130,267 — endered legal services in the amount of $130,267 and $248,272, respectively, to the Comp
• $248,272 — services in the amount of $130,267 and $248,272, respectively, to the Company. From Jul
• $144,517 — endered legal services in the amount of $144,517 to the Company. These transactions were
• $120,000 — s, in which the amount involved exceeds $120,000 and such person would have a direct or

Filing Documents

• ea0218812-01.htm (DEF 14A) — 1432KB
• tinmed_logo.jpg (GRAPHIC) — 111KB
• tproxy_001.jpg (GRAPHIC) — 839KB
• tproxy_002.jpg (GRAPHIC) — 885KB
• 0001213900-24-091222.txt ( ) — 3961KB

From the Filing

DEF 14A 1 ea0218812-01.htm PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________ SCHEDULE 14A _____________________________________ Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     ) Filed by the Registrant   ☒ Filed by a Party other than the Registrant   Check the appropriate box:   Preliminary Proxy Statement   Confidential, for Use of the Commission Only (as permitted by Rule 14a -6 (e)(2)) ☒   Definitive Proxy Statement   Definitive Additional Materials   Soliciting Material under §240.14a -12 INMED PHARMACEUTICALS INC. (Name of Registrant as Specified In Its Charter) ___________________________________________________________ (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box) ☒   No fee required.   Fee paid previously with preliminary materials.   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a -6 (i)(1) and 0 -11 .   INMED PHARMACEUTICALS INC. NOTICE OF ANNUAL GENERAL MEETING AND MANAGEMENT INFORMATION CIRCULAR OCTOBER 28, 2024 This proxy statement and management information circular is dated October 28, 2024, and is first being made available to shareholders on or about October 28, 2024.   INMED PHARMACEUTICALS INC. Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TAKE NOTICE that the annual general meeting (the “ Meeting ”) of the shareholders (the “ Shareholders ”) of INMED PHARMACEUTICALS INC. (“ InMed ” or the “ Company ”) will be held virtually on Wednesday, December 18, 2024, at 4:00 p.m., Pacific Standard Time, for the following purposes: 1.        to receive the audited consolidated financial statements of the Company, together with the auditor’s report thereon, for the year ended June 30, 2024; 2.        to elect five directors of the Company named in the accompanying proxy statement and management information circular (the “ Information Circular ”) to hold office until the next annual meeting of the Shareholders of the Company or until their successors are duly elected; 3.        to re -appoint Marcum LLP as the auditor/independent registered public accounting firm of the Company for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors; and 4.        to transact such other business as may properly come before the Meeting or any adjournment(s) or postponement(s) thereof. The Company elected to conduct the Meeting virtually again this year, in order to maximize Shareholder attendance for those who would be unable to attend in person. The Meeting will be held in virtual only format, which will be conducted via telephone conference. You will not be able to attend the Meeting in person. All Shareholders, regardless of their geographic location, will have an equal opportunity to participate in the Meeting. We remain committed to ensuring that Shareholder meetings encourage Shareholder participation and engagement and to making the Meeting accessible and engaging for all involved. Registered Shareholders and validly appointed proxyholders can access the meeting by using the following dial -in details for the call: Canada/USA Toll Free:   +1.844.763.8274 International Toll:   +1.647.484.8814 The Meeting will begin promptly at 4:00 p.m. Pacific Standard Time. Access to the Meeting will open 15 minutes prior to the start of the Meeting. We encourage you to access the Meeting in advance of the designated start time. Registered Shareholders and validly appointed proxyholders who attend the Meeting will have an equal opportunity to participate at the Meeting, regardless of their geographic location. As permitted by Canadian securities regulators and the U.S. Securities and Exchange Commission (“ SEC ”), the Company has elected to use notice -and -access provisions under National Instrument 54 -101 and National Instrument 51 -102 and applicable SEC rules (collectively, the “ Notice and Access Provisions ”) for this Meeting. Notice and Access Provisions are a set of rules developed by the Canadian Securities Administrators and the SEC that reduce the vol

View Full Filing

View this DEF 14A filing on SEC EDGAR